Compare MGIC & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MGIC | CGEN |
|---|---|---|
| Founded | 1983 | 1993 |
| Country | Israel | Israel |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 990.3M | 143.1M |
| IPO Year | 1991 | 2000 |
| Metric | MGIC | CGEN |
|---|---|---|
| Price | $26.95 | $1.63 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $18.00 | $4.00 |
| AVG Volume (30 Days) | 39.1K | ★ 458.5K |
| Earning Date | 11-18-2025 | 11-10-2025 |
| Dividend Yield | ★ 2.22% | N/A |
| EPS Growth | ★ 16.15 | N/A |
| EPS | ★ 0.81 | N/A |
| Revenue | ★ $603,216,000.00 | $6,903,000.00 |
| Revenue This Year | $12.87 | N/A |
| Revenue Next Year | $6.23 | $231.15 |
| P/E Ratio | $33.45 | ★ N/A |
| Revenue Growth | ★ 12.65 | N/A |
| 52 Week Low | $11.36 | $1.13 |
| 52 Week High | $27.44 | $2.66 |
| Indicator | MGIC | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 57.18 | 54.27 |
| Support Level | $26.61 | $1.43 |
| Resistance Level | $27.31 | $1.73 |
| Average True Range (ATR) | 0.70 | 0.07 |
| MACD | -0.08 | 0.02 |
| Stochastic Oscillator | 80.65 | 63.33 |
Magic Software Enterprises Ltd is a software development company. The company's operating segment includes Software Services and IT Professional Services. The company generates maximum revenue from the IT Professional Services segment. IT Professional Services segment offers IT services in the areas of infrastructure design and delivery, application development, technology planning and implementation services, communications services and solutions, as well as supplemental outsourcing services. Geographically, it derives a majority of revenue from the United States and also has a presence in Israel, Europe, Japan, and Other countries.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.